Sanofi, Glaxo Covid shot works as booster, but release pushed back

Sanofi shares dropped less than 1% in Paris trading, as did Glaxo in London

Sanofi and GlaxoSmithKline Plc, the pharma giants that stumbled in the race to develop a Covid-19 shot, said their experimental vaccine works as a booster but suffered yet another delay with the main clinical trial results.
 

The booster raised the antibody levels of people who’d already received other inoculations such as Pfizer Inc.’s and AstraZeneca Plc’s, the drugmakers said in a statement Wednesday. Crucial test results for the underlying vaccine, meanwhile, were pushed back to the first quarter. Neither study pitted the product against the new omicron variant. 

The two partners took the unusual step of saying their shot works as